These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 29293235)

  • 1. The struggle to do no harm in clinical trials.
    Schmidt C
    Nature; 2017 Dec; 552(7685):S74-S75. PubMed ID: 29293235
    [No Abstract]   [Full Text] [Related]  

  • 2. Making cancer immunotherapy a surer bet.
    Eisenstein M
    Nature; 2017 Dec; 552(7685):S72-S73. PubMed ID: 29293218
    [No Abstract]   [Full Text] [Related]  

  • 3. [Immunotherapy in lung cancer: checkpoint inhibitors].
    Wehler T; Wehler B; Stehle I
    Dtsch Med Wochenschr; 2015 Dec; 140(24):1835-8. PubMed ID: 26625234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Part I: Checkpoint inhibitors in cancer therapy.
    Daud AI
    Immunotherapy; 2016 Jun; 8(6):675-6. PubMed ID: 27197535
    [No Abstract]   [Full Text] [Related]  

  • 5. Attack of the killer clones.
    Scudellari M
    Nature; 2017 Dec; 552(7685):S64-S66. PubMed ID: 29293233
    [No Abstract]   [Full Text] [Related]  

  • 6. Cancer treatment: The killer within.
    Ledford H
    Nature; 2014 Apr; 508(7494):24-6. PubMed ID: 24695297
    [No Abstract]   [Full Text] [Related]  

  • 7. The immune checkpoint inhibitors: where are we now?
    Webster RM
    Nat Rev Drug Discov; 2014 Dec; 13(12):883-4. PubMed ID: 25345674
    [No Abstract]   [Full Text] [Related]  

  • 8. Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.
    O'Kane GM; Labbé C; Doherty MK; Young K; Albaba H; Leighl NB
    Oncologist; 2017 Jan; 22(1):70-80. PubMed ID: 27534573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy Combinations in Multiple Myeloma - Known Unknowns.
    Gormley NJ; Pazdur R
    N Engl J Med; 2018 Nov; 379(19):1791-1795. PubMed ID: 30403935
    [No Abstract]   [Full Text] [Related]  

  • 10. Sudden hearing loss in a melanoma patient on pembrolizumab: an etiology not to be omitted in the differential diagnosis.
    Nader ME; Myers JN; Gidley PW
    J Immunother Cancer; 2017; 5():24. PubMed ID: 28331614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The double edge of cancer immunotherapy.
    Nat Med; 2017 Feb; 23(2):137. PubMed ID: 28170382
    [No Abstract]   [Full Text] [Related]  

  • 12. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
    Spain L; Larkin J
    Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
    [No Abstract]   [Full Text] [Related]  

  • 13. Cancer immunotherapy: Progress and challenges in the clinical setting.
    Zarour HM; Ferrone S
    Eur J Immunol; 2011 Jun; 41(6):1510-5. PubMed ID: 21618503
    [No Abstract]   [Full Text] [Related]  

  • 14. Programmed death protein 1 inhibitors making inroads in multiple cancers.
    Brower V
    J Natl Cancer Inst; 2015 May; 107(5):. PubMed ID: 25957444
    [No Abstract]   [Full Text] [Related]  

  • 15. Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer.
    Rossi E; Sgambato A; De Chiara G; Casaluce F; Losanno T; Sacco PC; Santabarbara G; Gridelli C
    Expert Rev Clin Pharmacol; 2016; 9(3):419-28. PubMed ID: 26681547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity.
    Inno A; Metro G; Bironzo P; Grimaldi AM; Grego E; Di Nunno V; Picasso V; Massari F; Gori S
    Tumori; 2017 Sep; 103(5):405-421. PubMed ID: 28497847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-Analysis of the Risk of Immune-Related Adverse Events With Anticytotoxic T-Lymphocyte-Associated Antigen 4 and Antiprogrammed Death 1 Therapies.
    Komaki Y; Komaki F; Yamada A; Micic D; Ido A; Sakuraba A
    Clin Pharmacol Ther; 2018 Feb; 103(2):318-331. PubMed ID: 28118483
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the checkpoint protein PD-1 by the therapeutic antibody pembrolizumab outlined by quantum chemistry.
    Tavares ABMLA; Lima Neto JX; Fulco UL; Albuquerque EL
    Sci Rep; 2018 Jan; 8(1):1840. PubMed ID: 29382901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TNF blockade and cutaneous lupus erythematosus: where do we stand and where are we going?
    Zattra E; Stan R; Russo I; Lo Nigro A; Peserico A; Alaibac M
    Immunotherapy; 2013 Aug; 5(8):791-4. PubMed ID: 23902545
    [No Abstract]   [Full Text] [Related]  

  • 20. American Association of Cancer Research Showcases Immunotherapy Advances.
    Brower V
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 26243202
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.